cannabis patient care
|
vol. 3 no. 3 cannapatientcare.com
4
c a n n a b i s s c i e n c e a n d t e c h n o l o g y
®
o c t o b e r 2 0 2 2 | v o l 3 • n o 3
editorial advisory
board members
Cannabis Patient Care
®
's Editorial Advisory Board is a group of
distinguished individuals assembled to help the publication
fulfill its editorial mission to educate the medical community
on the viable treatment options patients are experiencing
with cannabis and the on-going research into cannabis
and cannabinoids world-wide. With recognized expertise
ranging from medical research, advocacy work, and personal
experience as patients, board members perform a range of
functions, such as suggesting authors and topics for coverage
and providing the editor with general direction and feedback.
We are indebted to these individuals for their contributions to
the publication and to the cannabis community as a whole.
STANLEY ATKINS
The Good Medic LLC
ANN BRUM
Joint Venture & Co
JOSHUA CROSSNEY
Founder, Cannabis
Science Conference
ME FUIMAONO -POE
Family Nurse
Practitioner at The
Malie Cannabis
Clinic The Queen's
Medical Center
DR . JEFF KONIN,
Clinical Professor
and the Director of
the Doctor of Athletic
Training Degree at
Florida International
University
STEPHEN MANDILE
Veteran & activist
HEATHER
MANUS, RN
Cannabis Nurses
Network
DR . MARION
MCNABB
Cannabis Center of
Excellence, Inc.
PATRICIA A .
PATTON
Cannabis Business
Alliance and
Cannaboomer Strategic
Patients Continue Turning
to Medical Cannabis
AS YOU'LL SEE throughout the pages of this issue of Cannabis Pa-
tient Care, health care professionals are routinely fielding ques-
tions from their patients about medical cannabis and in some
cases, even advising patients about addressing the problemat-
ic symptoms of chemotherapy-induced peripheral neuropathy
(CIPN) for children with cancer.
And it's not just children who are benefiting from symptom re-
lief. For example, in a recently published article in our sister pub-
lication, Contemporary OBGYN (1), research from the North Amer-
ican Menopause Society (NAMS) suggested that many women are
turning to medical cannabis as an adjunctive treatment for men-
opause-related symptoms (2). In that study, researchers surveyed
258 women—131 perimenopausal and 127 postmenopausal—to
learn more about their patterns of medical cannabis use. Most of
the women surveyed reported current cannabis use (86%) and en-
dorsed it to help with menopause-related symptoms (79%). Smok-
ing was the most common method of use (84%), followed by ed-
ibles (78%). Researchers found that women were primarily using
cannabis to address sleep disturbances (67%) and mood/anxiety
(46%). In a related interview at Cannabis Science Conference East,
which you can view on our website, Dr. Dustin Sulak noted that he
has seen medical cannabis help women with menopausal symp-
toms and explained the potential benefits (3).
While previous research suggests that cannabis use can im-
prove anxiety, mood, sleep, pain, and even cognition after certain
treatments, more research is necessary to determine its over-
all potential use for different conditions. As more pharmaceuti-
cal companies become involved in clinical trials of medical canna-
bis in different patient populations, it will be exciting to see what
the future holds for this therapeutic option. Stay tuned and please
register at for upcoming meetings—such as the upcoming Canna-
bis Science Conference Spring April 19-21st in Portland, Oregon—
for more insights like these.
Mike Hennessy Jr
PRESIDENT AND CEO
References
(1) L. Carr, Contemporary OBGYN, https://www.contemporaryobgyn.net/view/medical-
cannabis-popular-among-patients-with-menopause-related-symptoms
(2) M.K. Dahlgren, C. El-Abboud, A.M. Lambros, K.A. Sagar, R.T. Smith, and S.A.
Gruber, A survey of medical cannabis use during perimenopause and
postmenopause [published online ahead of print, 2022 Aug 2]. Menopause.
2022;10.1097/GME.0000000000002018. doi:10.1097/GME.0000000000002018
(3) https://www.cannapatientcare.com/view/dr-dusin-sulak-on-older-adults-
and-women-s-health-the-role-of-cannabis-and-psychedelics
Note from
the CEO
